Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan;23(1):25-28.
doi: 10.1016/S1473-3099(22)00792-7. Epub 2022 Dec 5.

Effect of hybrid immunity and bivalent booster vaccination on omicron sublineage neutralisation

Markus Hoffmann  1 , Georg M N Behrens  2 , Prerna Arora  3 , Amy Kempf  3 , Inga Nehlmeier  4 , Anne Cossmann  5 , Luis Manthey  5 , Alexandra Dopfer-Jablonka  5 , Stefan Pöhlmann  3
Affiliations

Effect of hybrid immunity and bivalent booster vaccination on omicron sublineage neutralisation

Markus Hoffmann et al. Lancet Infect Dis. 2023 Jan.
No abstract available

PubMed Disclaimer

Conflict of interest statement

AK, IN, SP, and MH have done contract research (testing of vaccinee sera for neutralising activity against SARS-CoV-2) for Valneva unrelated to this work. GMNB served as advisor for Moderna. SP served as advisor for BioNTech, unrelated to this work. All other authors declare no competing interests. MH and GMNB are co-first authors of this study.

Figures

Figure
Figure
Omicron sublineage-specific neutralisation activity elicited upon triple vaccination, breakthrough infection, and monovalent or bivalent vaccine boosters. (A) Neutralising activity in patient plasma. Plasma samples were analysed from individuals who were (i) triple vaccinated (n=16), (ii) triple vaccinated with a BTI during the BA.1 and BA.2 wave in Germany (n=17), (iii) triple vaccinated with a BTI during the BA.5 wave in Germany (n=27), (iv) triple vaccinated that received the monovalent BNT162b2 (Pfizer–BioNTech) vaccine booster (n=11), (v) triple vaccinated with a subsequent monovalent BNT162b2 vaccine booster and a BTI during the BA.5 wave in Germany (n=8), (vi) triple vaccinated individuals with a subsequent bivalent BNT162b2 original and omicron BA.4-5 vaccine booster (n=21), (vii) or triple vaccinated with a BTI during the BA.1 and BA.2 wave in Germany and a subsequent bivalent BNT162b2 original and omicron BA.4-5 vaccine booster (n=11). Information on the methods and statistical analysis are reported in the appendix (pp 10–12). (B) Individual analysis of vaccinated cohorts without BTI. Information on the methods and statistical analysis are reported in the appendix (pp 10–12). Dashed lines indicate the lowest plasma dilution tested. Of note, all samples yielding an NT50 value of less than 6·25 (starting dilution of 1:25) or 12·5 (starting dilution of 1:50) were considered negative and were assigned an NT50 value of 1. BTI=breakthrough infection. NT50=neutralising titre 50. Recipr. dilution factor=reciprocal dilution factor. V=vaccination.
Figure
Figure
Omicron sublineage-specific neutralisation activity elicited upon triple vaccination, breakthrough infection, and monovalent or bivalent vaccine boosters. (A) Neutralising activity in patient plasma. Plasma samples were analysed from individuals who were (i) triple vaccinated (n=16), (ii) triple vaccinated with a BTI during the BA.1 and BA.2 wave in Germany (n=17), (iii) triple vaccinated with a BTI during the BA.5 wave in Germany (n=27), (iv) triple vaccinated that received the monovalent BNT162b2 (Pfizer–BioNTech) vaccine booster (n=11), (v) triple vaccinated with a subsequent monovalent BNT162b2 vaccine booster and a BTI during the BA.5 wave in Germany (n=8), (vi) triple vaccinated individuals with a subsequent bivalent BNT162b2 original and omicron BA.4-5 vaccine booster (n=21), (vii) or triple vaccinated with a BTI during the BA.1 and BA.2 wave in Germany and a subsequent bivalent BNT162b2 original and omicron BA.4-5 vaccine booster (n=11). Information on the methods and statistical analysis are reported in the appendix (pp 10–12). (B) Individual analysis of vaccinated cohorts without BTI. Information on the methods and statistical analysis are reported in the appendix (pp 10–12). Dashed lines indicate the lowest plasma dilution tested. Of note, all samples yielding an NT50 value of less than 6·25 (starting dilution of 1:25) or 12·5 (starting dilution of 1:50) were considered negative and were assigned an NT50 value of 1. BTI=breakthrough infection. NT50=neutralising titre 50. Recipr. dilution factor=reciprocal dilution factor. V=vaccination.
See this image and copyright information in PMC

Comment in

References

    1. Arora P, Zhang L, Rocha C, et al. Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3. Lancet Infect Dis. 2022;22:766–767. - PMC - PubMed
    1. Arora P, Kempf A, Nehlmeier I, et al. Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5. Lancet Infect Dis. 2022;22:1117–1118. - PMC - PubMed
    1. Sheward DJ, Kim C, Fischbach J, et al. Omicron sublineage BA.2.75.2 exhibits extensive escape from neutralising antibodies. Lancet Infect Dis. 2022;22:1538–1540. - PMC - PubMed
    1. Scheaffer SM, Lee D, Whitener B, et al. Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 omicron variant in mice. Nat Med. 2022 doi: 10.1038/s41591-022-02092-8. published online Oct 20. - DOI - PMC - PubMed
    1. Kurhade C, Zou J, Xia H, et al. Low neutralization of SARS-CoV-2 omicron BA.2.75.2, BQ.1.1, and XBB.1 by 4 doses of parental mRNA vaccine or a BA.5-bivalent booster. bioRxiv. 2022 doi: 10.1101/2022.10.31.514580. published online Nov 2. (preprint). - DOI - PubMed

Substances